tetracosactide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
synthetic polypeptides with a corticotropin-like action 4516 16960-16-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • corticotropin (1-24)
  • cosyntropin
  • tetracosactrin
  • tetracosapeptide
  • tetracosactide
  • tetracosactide acetate
  • tetracosactrin zinc
A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of ADRENOCORTICOTROPIC HORMONE. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of CORTICOSTEROIDS in the ADRENAL CORTEX.
  • Molecular weight: 2933.49
  • Formula: C136H210N40O31S
  • CLOGP: 0
  • LIPINSKI: 3
  • HAC: 71
  • HDO: 42
  • TPSA: 1158.72
  • ALOGS: -4.78
  • ROTB: 93

Drug dosage:

DoseUnitRoute
0.25 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
April 22, 1970 FDA AMPHASTAR PHARMS INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC H01AA02 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
ACTH
FDA CS M0000499 Adrenocorticotropic Hormone
MeSH PA D006728 Hormones
CHEBI has role CHEBI:33295 diagnostic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Cosyntropin preparation indication 126188005
Adrenal cortical hypofunction indication 386584007 DOID:10493
Diagnostic Test for Secondary Adrenocortical Insufficiency indication
West syndrome off-label use 28055006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.35 acidic
pKa2 4.08 acidic
pKa3 9.43 acidic
pKa4 10.05 acidic
pKa5 12.36 acidic
pKa6 12.72 acidic
pKa7 13.1 acidic
pKa8 13.34 acidic
pKa9 13.43 acidic
pKa10 13.64 acidic
pKa11 13.82 acidic
pKa12 13.87 acidic
pKa13 11.5 Basic
pKa14 11.26 Basic
pKa15 11.01 Basic
pKa16 10.81 Basic
pKa17 10.55 Basic
pKa18 10.3 Basic
pKa19 9.94 Basic
pKa20 7.62 Basic
pKa21 6.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Adrenocorticotropic hormone receptor GPCR AGONIST Ki 8.27 SCIENTIFIC LITERATURE CHEMBL
Melanocortin receptor 4 GPCR EC50 9.19 CHEMBL

External reference:

IDSource
D003366 MESH_DESCRIPTOR_UI
D00284 KEGG_DRUG
4018522 VUID
N0000146844 NUI
C0010192 UMLSCUI
72YY86EA29 UNII
2255 INN_ID
DB01284 DRUGBANK_ID
CHEBI:3901 CHEBI
6965 IUPHAR_LIGAND_ID
CHEMBL2103784 ChEMBL_ID
16129674 PUBCHEM_CID
325824002 SNOMEDCT_US
132939 MMSL
002115 NDDF
2890 RXNORM
4509 MMSL
d00607 MMSL
4018522 VANDF
96363002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cortrosyn HUMAN PRESCRIPTION DRUG LABEL 1 0548-5900 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 mg INTRAMUSCULAR NDA 10 sections
Cosyntropin HUMAN PRESCRIPTION DRUG LABEL 1 0781-3440 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 mg INTRAVENOUS ANDA 10 sections
Cortrosyn HUMAN PRESCRIPTION DRUG LABEL 1 50090-4547 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 mg INTRAMUSCULAR NDA 10 sections
Cortrosyn HUMAN PRESCRIPTION DRUG LABEL 1 52584-050 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 mg PARENTERAL NDA 10 sections
Cosyntropin HUMAN PRESCRIPTION DRUG LABEL 1 67457-227 INJECTION, POWDER, FOR SOLUTION 0.25 mg INTRAVENOUS ANDA 10 sections